OR WAIT null SECS
February 03, 2026
Walid Kamoun, PhD, and Alex Philippidis discuss AI’s Power to Lower Costs while Elucidating Tumor Progression, NVIDIA and Eli Lily’s Deal, and Revolution Medicine’s lack of a Deal.
January 07, 2026
In Episode 31, industry veteran Deborah Dunsire goes behind the headlines to discuss the current state of innovation and evolving drug development landscape.
December 17, 2025
In Episode 30, John Androsavich, Benjamin Fryer, and John Wilkerson go behind the headlines.
December 09, 2025
In Episode 29, John Androsavich, Benjamin Fryer and John Wilkerson go behind the top headlines from 2025.
November 06, 2025
In Episode 28, Miroslav Gasparek, Sensible; Lizzy Lawrence, STAT; and Joe Lewis, Deloitte, go behind the headlines.
October 22, 2025
In episode 27, Christopher Hopkins, PhD; Omkar Kawalekar, PhD; Barnaby Pickering; and Jerry Rosenbaum, MD, go behind the headlines.
October 01, 2025
Pfizer re-balances weight loss portfolio with Metsera, Bristol Myers Squibb and Roche make breast cancer progress, and Keytruda gets under your skin.
September 24, 2025
Alvin Jogasuria, ProBio; Matthew Lunning, University of Nebraska Medical Center; and Carl Schoellhammer, DeciBio, go behind the headlines to discuss the need for doing more with less.
September 09, 2025
Aaron Cowley, Recipharm Advanced Bio; Renee Hart, LumaCyte; and Vibha Jawa, EpiVax, go behind the headlines to delve deeper into recent market deals driven by Big Pharma patent cliffs and the complex manufacturing of ATMPs.
August 26, 2025
